Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | C1R | P00736 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 4/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE6A | P16499 | 1/20 | 0.41 |
| ▸ | PDE6G | P18545 | 1/20 | 0.41 |
| ▸ | PDE6B | P35913 | 1/20 | 0.41 |
| ▸ | PDE6C | P51160 | 1/20 | 0.41 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482350 | 0.86 | PDE5A (0.47) | MAPTMRGPRX4PDE6DPDE5APDE6A | |
| SCHEMBL2910799 | 0.85 | CFTR (0.49) | CFTRMAPTDYRK1APARP1 | |
| SCHEMBL5638035 | 0.82 | EGFR (0.47) | NQO2MRGPRX4EGFR | |
| SCHEMBL16168919 | 0.81 | GRM2 (0.49) | MAPTNQO2 | |
| SCHEMBL16759798 | 0.80 | CFTR (0.47) | CFTRMAPTPTGESDYRK1APARP1 | |
| SCHEMBL13919591 | 0.80 | CDK2 (0.49) | MAPTNOTUM | |
| SCHEMBL31405129 | 0.79 | SDHB (0.51) | C1RAGPAT2MRGPRX4PDE5A | |
| SCHEMBL26998967 | 0.79 | SDHB (0.51) | C1RAGPAT2MRGPRX4PDE5A | |
| SCHEMBL3281879 | 0.77 | KDM4E (0.60) | MAPTNQO2 | |
| SCHEMBL19579754 | 0.77 | CFTR (0.49) | CFTRMAPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008079683-A2 | N- (5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | CFTR 1391/4885MAPT 2392/4885C1R 317/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | CFTR 1341/4885MAPT 2573/4885C1R 337/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | CFTR 1391/4885MAPT 2392/4885C1R 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.